早期胰腺癌分子诊断专家共识(2023年版)  

Expert consensus on the molecular diagnosis of early-stage pancreatic cancer(2023 edition)

作　　者：中国医师协会临床精准医疗专业委员会 中国抗癌协会肿瘤胰腺病学专业委员会 肖桂山 郭俊超[3] 郭晓钟[4] Professional Committee on Clinical Precision Medicine,Chinese Medical Doctor Association;The Society of Pancreas Cancer,Chinese Anti-Cancer Association;XIAO guishan;GUO Junchao;GUO Xiaozhong

机构地区：[1]不详 [2]大连理工大学 [3]中国医学科学院北京协和医院 [4]中国人民解放军北部战区总院

出　　处：《临床肝胆病杂志》2024年第3期473-477,共5页Journal of Clinical Hepatology

基　　金：国家自然科学基金(81770846,81642006);Hirshberg胰腺癌研究基金(AH201901083);康德生物癌症研究基金(KD2021030001)。

摘　　要：胰腺癌是一种较为常见的消化系统肿瘤,早期诊断困难,恶性程度极高。以肿瘤生物标志物为核心的分子辅助诊断技术,结合现有临床金标准,对于实现早期精准检测、及时治疗干预及降低病死率具有重要的临床意义。研究证实,微小RNA(miRNA)在胰腺肿瘤不同病理时期出现的种类和表达量变化呈现高度特异性,可用于胰腺肿瘤发生、发展的全程监测。单个miRNA的诊断潜力有限,miRNA组合或可有效提升对早期胰腺癌变的诊断性能。本共识基于近年相关研究进展,填补胰腺癌临床诊疗指南中关于分子诊断技术的空白,并提供专家指导意见。Pancreatic cancer is a relatively common tumor of the digestive system,with difficulties in early-stage diagnosis and an extremely high degree of malignancy.Molecular diagnostic technology based on tumor biomarkers,combined with the existing gold standard in clinical practice,is of great clinical significance to achieve early accurate identification,timely treatment and intervention,and reduction in mortality.Previous studies have shown that miRNAs show high specificity in terms of types and expression levels in different pathological stages of pancreatic cancer and can thus be used in monitoring the development and progression of pancreatic cancer.Since a single miRNA has a limited diagnostic potential,the combination of different miRNAs may effectively improve the diagnostic efficiency of early-stage pancreas carcinogenesis.Based on related research advances in recent years,this consensus document aims to fill the gap in molecular diagnostic technology in the guidelines for the clinical diagnosis and treatment of pancreatic cancer and provide expert guidance and recommendations.

关 键 词：胰腺肿瘤 癌症早期检测 生物标记 肿瘤 微RNAS 专家共识 

分 类 号：R735.9[医药卫生—肿瘤]